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Abstract
Background: At the end of the past century there were multiple concerns regarding lack of transparency in the conduct of
clinical trials as well as some ethical and scientific issues affecting the trials’ design and reporting. In 2000 ClinicalTrials.gov
data repository was developed and deployed to serve public and scientific communities with valid data on clinical trials.
Later in order to increase deposited data completeness and transparency of medical research a set of restrains had been
imposed making the results deposition compulsory for multiple cases.
Methods: We investigated efficiency of the results deposition and outcome reporting as well as what factors make positive
impact on providing information of interest and what makes it more difficult, whether efficiency depends on what kind of
institution was a trial sponsor. Data from the ClinicalTrials.gov repository has been classified based on what kind of
institution a trial sponsor was. The odds ratio was calculated for results and outcome reporting by different sponsors’ class.
Results: As of 01/01/2012 118,602 clinical trials data deposits were made to the depository. They came from 9068 different
sources. 35344 (29.8%) of them are assigned as FDA regulated and 25151 (21.2%) as Section 801 controlled substances.
Despite multiple regulatory requirements, only about 35% of trials had clinical study results deposited, the maximum
55.56% of trials with the results, was observed for trials completed in 2008.
Conclusions: The most positive impact on depositing results, the imposed restrains made for hospitals and clinics. Health
care companies showed much higher efficiency than other investigated classes both in higher fraction of trials with results
and in providing at least one outcome for their trials. They also more often than others deposit results when it is not strictly
required, particularly, in the case of non-interventional studies.
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Introduction
Clinical studies are important and one of the biggest part of
modern health care research in US. Besides they are ones of the
most expensive and, dealing with human subject and people
health, required to be done with a special care. At the end of the
past century there were multiple concerns regarding lack of
transparency in the conduct of clinical trials as well as some ethical
and scientific issues affecting the trials’ design and reporting [1,2].
In response on request to increase transparency of medical
research and novel drugs development, the Food and Drug
Administration issued a Modernization Act, Section 113 of which
required the development of a data registry [3]. So, in February
2000 ClinicalTrials.gov data repository was developed and
deployed (Zarin, 2010 Everything You Ever Wanted to Know About
ClinicalTrials.gov, on-line presentation). At that time it was designed to
help potential participants find trials, and was primarily focused on
people with serious or life-threatening conditions. Since then
through careful review process it was substantially improved to
become more complete and accurate. In September 2007 Food
and Drug Administration Amendments Act (FDAAA) was enacted
with a legal requirement of trials registration for a broader group
of trials than had previously been required under FDAMA [4]. In
2008, a database for reporting summary results was added to the
registry [5]. Today technological advancement in large scale data
processing, internet speed and cheap and getting cheaper
electronic storage devices gives us an opportunity to deal with
large scale data obtained from multiple sources and get a bigger
picture of a clinical study.
In recent years there were several papers related to clinical
trials: general reviews of clinical data repository ClinicalTrials.gov
progress and development [5–7], investigation on how likely and
soon a trial registered with ClinicalTrials.gov will result in a peer
reviewed publication [8,9], concerns related to completeness of an
outcome in the trials reporting [10], and rigorous study of
comparative effectiveness and its relationship to funding sources
[11].
Characteristic feature of the previous research is that one or
other kind of selection has been performed rather than meta-
analysis of all data available. Another point with lack of attention,
in our opinion, is classification of institutions sponsoring/
conducting a trial.
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IIn this study we performed overall meta-analysis of the clinical
trials deposited into ClinicalTrials.gov repository as of January 1,
2012; developed advanced classification of trials sponsors and
compare the results for different classes in two most important
aspects of the deposited information: outcome reporting and
deposition of clinical results data. Also we tried to decipher what
factors make the results and outcome reporting more plausible or
more difficult and whether it depends on the sponsor.
Methods
Data
Now significant number of clinical study records got public and
everybody can download them from the site in a well structured
format that makes the data processing easier and allows to keep
the original structure and reduce potential errors usually occurring
when plain text data need to be processed. We took the
opportunity downloaded, processed and analyzed the data trying
to decipher interesting regularities and to gain insight into the state
of clinical research.
Data has been obtained from ClinicalTrials. gov repository. The
last update has been done on 01/01/2012 and should contain all
the clinical trials records as of the pointed date. The data were
downloaded and imported into an in-house database. They were
obtained in XML format, so all preexisting formatting has been
saved. Parsing has been done by in-house developed perl script
utilizing XML::Simple library for ease of XML parsing.
Enhancement and Information Retrieval
While different kind of institutions take part in clinical research,
they can be one of two types: for- or non-profit. Moreover, non-
profit institutes are far non homogeneous among themself, they
can have fairly different goals, primary duties, and follow different
kind of regulations. So, in relation to a clinical trial the difference
between a national institute and a hospital may be as big as
between a university and a pharmaceutical company. Therefore,
in the presented study non-profits have been further subdivided
into four classes: Research/Educational Institutions (edu) consist-
ing of universities, colleges, academia, and other alike institutes
primarily focused on research and education; Hospitals & clinics
(hos) - organizations with primary focus on providing health care
service for people with health issues; collaborations including
associations, networks and other non-government institutions able
to include in itself different kind of participants (col) and national
and government organizations (gov). For-profit sponsors were put
into one class (com), including itself pharmaceutical and other
commercial companies of health care sector conducted and
deposited trials’ data. Classification schema is shown in Fig. 1.
One has to note that the original data had sponsors classification.
Namely, original classification had four classes: ‘Industry’, ‘NIH’,
‘Other’, and ‘U.S. Fed.’ We enhanced and slightly altered it in the
way that ‘NIH’ and ‘U.S. Fed’ classes were joined into one class
(gov). This class was extended to include other non US national
and governments sponsored institutions. (com) class is quite
consistent with ‘Industry’ in the original classification. And ‘Other’
has been distributed primarily into col, hos and edu classes.
Classification has been performed by in house text-mining
classificator designed as:
1. define keywords for a given class (like ‘University’,’College’,
‘Universita `’, etc. for edu class; ‘Hospital’, ‘Clinics’, ‘Ho ˆpitaux’,
‘Klinik’, etc. for hos class; ‘Company’, ‘Inc.’, ‘Corp.’, etc. for
companies);
2. make dictionaries for each class;
3. define priorities, like ‘Hospital’ has higher priority than
‘University’ or ‘College’ in other words ‘University Hospital’
will be classified as hos rather than edu.
We passed all records through the classificator, with supple-
mentary classification of records, which did not passed through,
using agency class information from original classification of the
sponsors. We used a leading sponsor of the trial in the
classification. Then partial manual inspection and corrections
were made.
So, we got trials distribution into classes as shown in Table 1.
Overall correspondence between the depository classification
and one described in this paper is shown in Table 2.
One has to note, that it is very tricky to make a precise
classification for over 118,000 trials coming from over 9,000
different sources, especially taking into account that deposits have
been made from different countries and therefore, the sponsors are
pointed in different languages. Besides, as it often happens, the
texts may have multiple typographic errors. So, eventually our
classification may have some errors but we do believe that it is not
significant taking into account the set size. After the automatic
classification manual refinement of the results has been made.
Statistical Analysis
Since 1951 medical statisticians use the odds ratio (OR) as
a measure of effect size, to describe the strength of association
or non-independence between two binary data characteristics
[12]. It is used as a descriptive statistic, where results are rather
qualitative than quantitative or an answer on a question is
either ‘yes’ or ‘no’. That perfectly suites our research of
reporting clinical trials results and outcomes (for each trial one
either has been reported or not). Additional beneficial feature of
the odds ratio for our study is that it can be estimated using
some types of non-random samples. The trials in the depository
are definitely non-random taking into account that one sponsor
usually deposits more than one trial.
So, we performed the odds ratio calculation as
OR~
p11p00
p10p01
where pyx comes from the joint distribution of two binary random
variables X and Y
Y~1Y ~0
X~1 p11 p10
X~0 p01 p00
in our case:
X =1 if results were deposited (outcome reported), 0 otherwise,
Y =1 if the trial has been classified as belonging to a given class
(edu, com, gov, hos), 0 otherwise.
Figure 1. Schema of the classification.
doi:10.1371/journal.pone.0037847.g001
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package (www.r-project.org), using t-test distribution and 95%
confidence level.
Results and Discussion
As of 01/01/2012 118,602 clinical trials data deposits were
made to the depository. They came from 9068 different sources.
35344 (29.8%) of them are assigned as FDA regulated and 25151
(21.2%) as Section 801 controlled substances. 70929 (60%) trials
had a treatment purpose.
To get a bigger picture, we calculated how number of started
and completed trials progresses year over year from the lunch of
the depository. 2011 was the only year through the decade of the
repository existence when the number of trials completed
exceeded the number of trials started (Fig. 2). In 2009 number
of trials started came to some kind of saturation. Interestingly, it
happened after the last recession (12/2007–6/2009) and the
recession itself did not made a notable impact on clinical trials
research (US Business Cycle Expansions and Contractions, http://www.
nber.org/cycles.html).
Another interesting feature we have observed, came from the
distribution of trials among phases (1–4) for investigated classes
(Fig. 3). For companies the number of trials per phase increases to
phase 3, then it drops, gov and col classes have maximum at
phase 2, while educational/research institutions have more trials
for phase 4 than for phase 3. Currently we do not have an
explanation for this phenomenon but would like to present it for
community discussion.
The Results and Outcome Reporting
In order to better understand drug safety and efficacy,
biomedical community has to have clinical trials results not just
a brief description. They also very important for establishing
effectiveness measures ‘‘doing the right trials’’ [13]. So, availability
of clinical results to public became one of the biggest concerns in
clinical research [1,5]. Besides, recently investigators have found
that reporting, even among registered trials, was done selectively
[14]. In response to these concerns, since 2007 FDAAA regulation
requires to deposit the study results in case ‘‘all of the drugs,
biologics, or devices used in that study have been approved by the
FDA for at least one use’’ [4]. At the same time, the use of such
registries as ClinicalTrials.gov has been demanded by the
International Committee of Medical Journal Editors (ICMJE).
As of 2005 the ICMJE has required trial registration before
participant enrollment as a prerequisite for publication in any of its
member journals [15].
Taking into account described above concerns as well as
multiple efforts taken in recent years to achieve research trans-
parency, spread from the FDA requirements to scientific
publications in peer reviewed journals [16], we investigated how
many trials have the results uploaded into the result database and
what factors or regulations were more stimulating than others.
Summary statistics for the deposits year-by-year, obeying different
imposed requirements is given in Tables 3,4.
Overall, only 4927 (4%) of the deposits had reported clinical
results and 6.82% of completed trials (having completion date as of
12/31/2011 or earlier). Certainly cumulative effect of taking into
account all the imposed requirements as:
N a trial has to be completed as assigned in its overall status;
N FDA and specifically Section 801 regulations;
N availability of references to a peer reviewed journal (particu-
larly ICMJE members);
N explicit notice of the phase (from 2 to 4);
N description of the study type as ‘interventional’
gives better chance for scientific community and general public
to see the results but it still does not seems to be enough. Overall
the cumulative requirements returned only about 35% of trials
with the deposited results with the maximum 55.56% for trials
completed in 2008. That means 3 years ago from the dates of the
current analysis, while according to the FDA regulations the
results have to be reported within 12 months of the completion
date as it is specified in the filings. Section 801 of FDAAA
requiring mandatory disclosure of specific clinical trial information
Table 1. Classification of trials’ sponsors.
Research/Educational Institutions (edu) Universities, colleges, academia, research institutes 32295 trials (27.2%)
Companies (com) pharmaceutical and other for-profit businesses of
health care sector
38018 trials (32.1%)
National and Government Organizations (gov) federal, municipal, and other government kind of
sponsored non-profit organizations
19414 trials (16.4%)
Hospitals & Clinics (hos) hospitals & clinics sponsoring clinical trials 17198 trials (14.5%)
Collaborations (col) organizations involving different institutions 10011 trials (8.4%)
Brief description and absolute and relative number of trials deposited into ClinicalTrials.gov 01/01/2012.
doi:10.1371/journal.pone.0037847.t001
Table 2. Correspondence between classification described in
this paper and one present in the ClinicalTrials.gov repository.
class (current) class (original) number of trials
com Industry 37076
Other 942
edu Other 32118
Industry 177
gov U.S. Fed 1974
NIH 9197
Industry 776
Other 7467
col Other 9851
Industry 160
hos Other 17198
unclassified Other 1666
doi:10.1371/journal.pone.0037847.t002
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ance and authorizing penalties for noncompliance [4], alone has
the highest impact on the results depositing. At the same time we
note that 4701 trials do not obey any of the investigated
requirements, set for the results deposition (or eventually it is not
pointed explicitly in the filings) but trials’ conductors/sponsors
deposited the results anyway.
The next point of our research was to check whether the trials
data are different for different responsible institutions (sponsors).
We look for how deposition of the results varies among different
classes of sponsoring the trials institutions, taking into account all
the applied regulations. It appears, government backed organiza-
tions less than others comply with the policy to deposit results of
clinical trials. Industrial companies demonstrated the best perfor-
mance in this aspect. And that would be expected taking into
account that they have higher fraction of new drug applications
and, therefore, more trials obeying restrictions imposed by the
FDA regulations. Detailed statistics is present in Table 5.
Also clinical trials design and reporting policy requires
investigators to disclosure outcomes of the conducted trials. This
has well grounded reasons, at first, trial participants have the right
to know abut known (from the previous study) risk by participating
in trials. Secondly, public availability of this information will
benefit next generation of clinical researchers and provides more
rational use of healthcare resources. Eventually, outcome report-
ing may be biased, moreover, some researchers state that the bias
occurs regardless of the funding source [17,18], others claim that
pharmaceutical industry companies are more prone to the bias
[8,19,20]. Namely, the previous research showed that trials’
conductors are more enthusiastic for positive outcome reporting in
literature [8]. Two aspects make this very likely: firstly, a paper
with no results to show or describing something that did not went
Figure 2. Number of trials started and completed each year since launching ClinicalTrials.gov repository.
doi:10.1371/journal.pone.0037847.g002
Figure 3. Number of trials assigned to different phases.
doi:10.1371/journal.pone.0037847.g003
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companies there is no point to publish a negative outcome, since
there is no peer reviewed publications in FDA requirements and
a publication for them has rather an advertisement purpose. But
depositing results and describing outcome in the repository gives
community better chances to see how the trial has been conducted
in detail and definitely is not so time and efforts consuming as
writing a full paper. How different investigated classes use this
opportunity?
4 of 5 assigned classes have very similar outcome reporting
statistics close to 3/4 of deposits, while government class provides
outcome description significantly more seldom than others.
Educational/research class provides more comprehensive out-
come description reporting more often not only the primary one
but the secondary as well. Overall statistics for outcome reporting
is considerably more optimistic than one for the results data being
submitted into the repository. See Table 6 for details.
Odds Ratio
Switching from the data already known to an estimate of a future
efficiency in the results and outcome reporting we utilized the odds
ratio. Conceptually the odds of a successful event are defined as
the ratio of the probability of success over the probability of
failure. In our case OR allows us to estimate reporting efficiency as
the ratio of cases where the results or outcome have been
submitted into the depository (success) over cases where this has
not been done and compare classes of the suggested classification
to see whether the behavior is different depending on what kind of
institution is responsible for a conducted trial. Since here we focus
Table 3. Number of completed trials obeying imposed requirements with results and total, deposited into ClinicalTrials.gov.
completion year Overall FDA regulated Section 801
with results total % with results total % with results total %
2011 169 13945 1.21 114 4475 2.55 93 3134 2.97
2010 894 11732 7.62 593 3899 15.21 491 2649 18.54
2009 1270 10588 11.99 899 3795 23.69 750 2643 28.38
2008 1328 8869 14.97 959 3084 31.1 814 2244 36.27
2007 385 6515 5.91 253 1464 17.28 190 990 19.19
2006 135 4714 2.86 99 848 11.67 56 523 10.71
2005 81 3632 2.23 61 657 9.28 32 408 7.84
2004 103 2076 4.96 90 530 16.98 31 333 9.31
2003 55 1337 4.11 52 389 13.37 16 248 6.45
2002 40 840 4.76 39 179 21.79 6 94 6.38
2001 16 547 2.93 16 84 19.05 9 47 19.15
2000 and before 20 1142 1.75 18 149 12.08 17 82 20.73
total 4496 65937 6.82 3193 19553 16.33 2505 13395 18.7
doi:10.1371/journal.pone.0037847.t003
Table 4. Number of completed trials obeying imposed requirements with results and total, deposited into ClinicalTrials.gov.
completion year phases 2–4 with publications interventional all requirements together
with results total % with results total % with results total % with results total %
2011 113 6200 1.82 16 495 3.23 156 11194 1.39 6 61 9.84
2010 638 5445 11.72 71 602 11.79 785 9440 8.32 24 84 28.57
2009 973 5316 18.3 96 659 14.57 1188 8811 13.48 47 111 42.34
2008 1079 4733 22.8 138 710 19.44 1262 7396 17.06 75 135 55.56
2007 306 3815 8.02 57 637 8.95 373 5610 6.65 26 85 30.59
2006 94 2795 3.36 27 454 5.95 131 4062 3.23 16 45 35.56
2005 47 2268 2.07 12 396 3.03 76 3181 2.39 9 46 19.57
2004 46 1323 3.48 15 255 5.88 103 1858 5.54 7 27 25.93
2003 21 824 2.55 5 138 3.62 53 1176 4.51 2 17 11.76
2002 6 434 1.38 3 95 3.16 40 689 5.81 1 5 20
2001 8 291 2.75 1 67 1.49 16 429 3.73 1 4 25
2000 and before 18 485 3.71 6 167 3.59 20 698 2.87 6 14 42.86
total 3349 33929 9.87 447 4675 9.56 4203 54544 7.71 220 634 34.7
doi:10.1371/journal.pone.0037847.t004
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intersects with others.
At first, we performed OR calculation for the entire set of trials.
Here one can see substantial difference between com class and
others in comparison of the results’ presence in the deposits
(Table 7). Also one has to note that for the government sponsored
class the OR is almost an order less than for others in outcome
reporting. While, others are fairly close to each other. In other
words, generally if a clinical trial has been conducted by a for-
profit company, we have a higher chance to get the study results
and outcome reported while the non-profit sector still needs
substantial improvement especially regarding results of its trials. In
this aspect our analysis does not support the previous research
where the researchers concluded that for trials funded by industry,
results reporting is less likely [21]. edu and hos classes are fairly
close in both outcome and results reporting.
Then we look for how the numbers change if we take into
account all mentioned above requirements, enforcing clinical
results data deposition. In this case the investigated pool shrank to
584 trials. Calculating OR for this reduced set one can see some
changes as for results as for the outcome reporting (Table 8).
Actually, the most positive impact on outcome reporting the
imposed restrains made for hospitals and clinics. For companies
both ratios got less than in no restrain case. Also now one can see
considerable difference in effectiveness of results and outcome
reporting for edu and hos classes. The restrains being developed
for the results deposition, somehow made positive impact on
outcome reporting for edu and gov classes. So, imposing restrains
lead to results reporting efficiency decrease for com, increase
substantially for hos, not significantly for edu and even less for
gov classes.
Interventions
Another characteristics impacting the reporting efficiency is
what kind of intervention (if any) had been performed in the trial.
Overall, top 3 intervention kinds are: drug, procedure and device.
While all investigated classes have higher interest in new drug
development. Companies are especially focused on drugs trials
(73% of interventional trials) and pay surprisingly little attention to
procedure development. For procedures the biggest contribution
comes from hospitals (Table 9). One of possible explanation,
coming from the data analysis, ‘procedure’ trials are often more
time consuming than other. Namely, average duration of a ‘drug’
trial deposited into the repository is about 984 days, while for
a ‘procedure’ trial it is 1302 days and a ‘device’ trial in average
lasts for 1048 days. We compared efficiency for different classes
and intervention types. Here efficiency is defined as percentage of
number of trials with results for given conditions (class, in-
tervention type) to the total number of trials for these conditions.
‘Procedure’ trials for all except hos classes have lower efficiency
in results reporting. For col and com ‘device’ trials have the
highest efficiency. For hos, gov and edu classes the highest
efficiency was observed for ‘drug’ trials.
Enrollment
Patient enrollment is one of the most important and time-
consuming aspects in clinical trials conduct. The depository
requires to provide information on how many arms has been in the
study and how many participants has been or anticipated to be
enrolled in the trial.
Looking through the decade of the data collection for how many
participants have been enrolled in a trial and how many arms
a trial had. Appear, the number of arms pretty much consistent
and in average is about 261 for all investigated classes. Data
regarding enrollment, seem more interesting. While Clinical-
Trials.gov general policy requires ‘‘Upon study completion,
change Type to Actual and update the enrollment’’ (Clinical-
Trials.gov Protocol Data Element Definitions http://prsinfo.clinicaltrials.
gov/definitions.html), number of participants enrolled in the trials
varies very widely from 0 to 99999999. 255 completed trials have
0 enrollment, 205 (80.4%) of them are interventional studies.
Neither of them had the results deposited but 66 (25.9%) of them
reported outcome of the study. 3 completed trials had 99999999
enrollment. All of them were classified as observational and
neither of them had results deposited or outcome reported.
Considering only completed trials with the results, minimum
enrollment became 1 and maximum enrollment became 2323608.
So, the results deposition substantially reduces the enrollment
range and adds confidence to the data. Providing the results allows
other researchers to get an idea of how to accomplish higher
enrollment into a trial. Particularly, in the trial NCT01236053
with the highest enrollment assigned (2323608 participants) it is
stated: ‘‘Patients were not recruited for nor enrolled in this study.
Table 5. Number of trials with results and overall obeying all
the imposed restrains as of 01/01/2012 for each assigned
class.
class trials with results total %
hos 21 65 32.31
edu 19 194 9.79
col 8 86 9.30
com 168 428 39.25
gov 10 156 6.41
doi:10.1371/journal.pone.0037847.t005
Table 6. Outcome reporting by different classes.
class
number of
trials with
at least one
outcome %
number of
trials with
more than
one outcome %
col 7288 72.8 2397 23.94
com 29433 77.42 10375 27.29
gov 7342 37.82 2182 11.24
hos 13197 76.74 4763 27.7
edu 24613 76.21 9758 30.22
doi:10.1371/journal.pone.0037847.t006
Table 7. Odds ratios and confidence intervals for four
investigated classes.
results outcome
OR CI OR CI
com 7.7789 (7.7779, 7.7799) 1.8245 (1.8220, 1.8269)
gov 0.1320 (0.1318, 0.1322) 0.1995 (0.1982, 0.2009)
hos 0.3983 (0.3980, 0.3986) 1.5609 (1.5591, 1.5627)
edu 0.3240 (0.3237, 0.3244) 1.6123 (1.6100, 1.6146)
All trials were taken into account.
doi:10.1371/journal.pone.0037847.t007
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medical records or insurance claims databases are anonymized
and used to develop a patient cohort. All diagnoses and treatments
are recorded in the course of routine medical practice’’.
The biggest overall variation was observed for government
sponsored sector. Hospitals, according to the presented data, have
an order higher enrollment than companies. That would be
expected taking into account hospitals’ primary mission. At the
same time, companies enrollment twice as big as one of
educational/research class (Table 10).
As we mentioned above the dispersion in the participants
enrollment will be significantly decreased if we will consider only
trials with reported outcome or submitted clinical results data. But
impact of these two restrains is not the same: somehow companies
have higher average enrollment for reported trial results than for
the outcome, while four other classes have considerably lower all
the numbers for trials with reported results. It would be expected
to have higher enrollment for observational rather than interven-
tional studies but somehow this impact is noted only for
collaborations and companies, comparatively to trials with
reported results. Also companies have more non-interventional
studies with reported results.
Though there is no statistical correlation between enrollment
and availability of deposited results, empirically, the bigger
assigned in the trial enrollment the less chance to have reported
results and/or an outcome.
More results of the meta-analysis are available at http://iicoll.
com/Analytics/clinical_trials_report_2012.html.
Conclusion
We investigated efficiency of results data depositionand outcome
reporting in ClinicalTrials.gov repository. Also we researched what
factors make positive impact on providing information of interest
and what makes it more difficult, as well as whether this depends on
what kind of institution is a sponsor of a trial.
While clinical results deposition is enforced up to the penalty by
the FDA and more than encouraged by International Committee
of Medical Journal Editors, overall the requirements making
results deposition obligatory, returned only about 35% of trials
with the deposited results, with the maximum 55.56% for trials
completed in 2008.
Though multiple previous research pointed that the industry
sector, corresponding com class in the current research, often has
lowerefficiency regarding presentation oftheir results inaliterature
[10,11,17]. Our study showed that completeness and efficiency of
com class deposits into ClinicalTrials.gov repository seems to be
muchhigherthanforotherclassesinmanyaspects:higherfractionof
Table 8. Odds ratios and confidence intervals for four
investigated classes.
results outcome
OR CI OR CI
com 3.66 (3.62, 3.7) 1.4 (1.36, 1.44)
gov 0.16 (0.15, 0.17) 0.45 (0.43, 0.48)
hos 1.59 (1.58, 1.61) 1.28 (1.26, 1.3)
edu 0.43 (0.42, 0.45) 1.76 (1.74, 1.79)
For trials possessing the results deposition restrains.
doi:10.1371/journal.pone.0037847.t008
Table 9. Number of trials and results reporting efficiency for three most popular intervention types.
class Drug Procedure Device
trials efficiency trials efficiency trials efficiency
col 2014 (48.85%) 0.65% 496 (12.03%) 0.20% 402 (9.75%) 1.74%
com 12156 (73.18%) 4.70% 349 (2.1%) 3.72% 2099 (12.64%) 5.91%
gov 3397 (53.99%) 0.62% 692 (11%) 0.14% 282 (4.48%) n/a
hos 2936 (39.17%) 1.77% 1498 (19.98%) 1.00% 848 (11.31%) 0.59%
edu 5739 (41.15%) 1.50% 2034 (14.58%) 0.98% 1307 (9.37%) 1.30%
doi:10.1371/journal.pone.0037847.t009
Table 10. Clinical trials enrollment for different classes.
class trials max average participants total
col 4495 2120000 1308.19 5880327
com 25873 4300000 1055.88 27318851
gov 9550 99999999 33298.38 317999544
hos 7410 67128927 9493.47 70346597
edu 15111 10050956 1812.4 27387147
with reported outcome
col 3295 2120000 1348.35 4442817
com 20634 4300000 801.89 16546258
gov 3633 200000 616.54 2239879
hos 5726 120000 287.34 1645327
edu 11583 2100000 1148.83 13306867
with clinical results deposited
col 105 59510 866.72 91006
com 3482 2323608 1553.2 5408229
gov 118 4241 276.21 32593
hos 248 3362 147.96 36694
edu 463 59696 416.86 193007
plus interventional study
col 97 6830 193 18744
com 3251 69274 478 1553678
gov 111 4241 268 29782
hos 235 1864 137 32195
edu 424 59696 417 176792
Overall status is ‘Completed’ or ‘Active, not recruiting’.
doi:10.1371/journal.pone.0037847.t010
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percentage in providing at least one outcome for the trials;
significantlyhigheroddsratiofortheresultsandslightlyaboveothers
for outcom e (overall) depositing. Companies deposit their results
evenwhenitisnotstrictlyrequired,particularly,theyhavemorenon-
interventional studies with reported results. Industrial sector dem-
onstrated the highest in average and total enrollment into its trails,
confirmed bydeposited resultdata.
The most positive impact on depositing results, the imposed
restrains made for hospitals and clinics. Somehow the restrains
also showed a positive influence on outcome reporting by
educational and research institutions. For health care companies
they did not seem to be an issue, moreover, both odds ratios got
less than in no restrains case.
Author Contributions
Conceived and designed the experiments: OK. Performed the experiments:
OK. Analyzed the data: OK. Contributed reagents/materials/analysis
tools: OK. Wrote the paper: OK.
References
1. Zarin DA, Tse T (2008) Medicine: moving toward transparency of clinical trials.
Science 319: 1340–1342.
2. Chan AW (2008) Bias, spin, and misreporting: time for full access to trial
protocols and results. PLoS Med 5: e230.
3. Public Law 105–115. Food and Drug Administration Modernization Act of
1997.
4. Public Law 110–95. Food and Drug Administration Amendments Act of 2007.
5. Zarin DA, Tse T, Williams RJ, Califf RM, Ide NC (2011) The ClinicalTrials.gov
Results Database – Update and Key Issues. N Engl J Med 364: 852–860.
6. Zarin DA, Tse T, Ide NC (2005) Trial Registration at ClinicalTrials.gov
between May and October 2005. N Engl J Med 353: 2779–2787.
7. Zarin DA, Ide NC, Tse T, Harlan WR, West JC, et al. (2007) Issues in the
registration of clinical trials. JAMA 297: 2112–2120.
8. Bourgeois FT, Murthy S, Mandl KD (2010) Outcome Reporting Among Drug
Trials Registered in ClinicalTrials.gov. Annals of Internal Medicine 153: 158–
166.
9. Ross JS, Tse T, Zarin DA, Xu H, Zhou L (2012) Publication of NIH funded
trials registered in ClinicalTrials.gov: cross sectional analysis. BMJ, 344: d7292.
10. Smyth RMD, Kirkham JJ, Jacoby A, Altman DG, Gamble G, et al. (2011)
Frequency and reasons for outcome reporting bias in clinical trials: interviews
with trialists. BMJ 342: 7153.
11. Bourgeois FT, Murth S, Mandl DK (2012) Comparative Effectiveness Research:
An Empirical Study of Trials Registered in ClinicalTrials.gov. PLoS One
10.1371.
12. Cornfield J (1951) A method for estimating comparative rates from clinical data:
Applications to cancer of the lung, breast and cervix. J Natl Cancer Inst 11:
1269–1275.
13. Dilts DM, Cheng SK (2012) The Importance of Doing Trials Right While
Doing the Right Trials. Clin Cancer Res 18: 3.
14. Ramsey S, Scoggins J (2008) Commentary: Practicing on the Tip of an
Information Iceberg? Evidence of Underpublication of Registered Clinical Trials
in Oncology. The Oncologist 13: 925–929.
15. International Committee of Medical Journal Editors (2004) Clinical trial
registration: a statement from the International Committee of Medical Journal
Editors. JAMA 292: 1363.
16. Thomas KB, Joergensen M, Lynch G, Rubison M, Porter BD, et al. (2010)
Clinical Trial Disclosure: Global Overview and Implications of New Laws and
Guidelines. Drug Information Journal 44: 213–225.
17. Chan AW, Hro ´bjartsson A, Haahr MT, Gøtzsche PC, Altman DG (2004)
Empirical evidence for selective reporting of outcomes in randomized trials:
comparison of protocols to published articles. JAMA 291: 2457–2465.
18. Hartling L, Craig WR, Russell K, Stevens K, Klassen TP (1992) Factors
influencing publication of research results: followup of applications submitted to
two institutional review boards. JAMA 267: 374–378.
19. Vedula SS, Bero L, Scherer RW, Dickersin K (2009) Outcome reporting in
industry-sponsored trials of gabapentin for off-label use. N Engl J Med 361:
1963–1971.
20. Lexchin J, Bero LA, Djulbegovic B, Clark O (2003) Pharmaceutical industry
sponsorship and research outcome and quality: systematic review. BMJ 326:
1167–1170.
21. Law MR, Kawasumi Y, Morgan SG (2011) Despite Law, Fewer Than One In
Eight Completed Studies Of Drugs And Biologics Are Reported On Time On
ClinicalTrials.gov. Health Aff 30: 2338–2345.
Results and Outcome Reporting
PLoS ONE | www.plosone.org 8 June 2012 | Volume 7 | Issue 6 | e37847